Highly significant discrepancies have been observed in measurements of various factor IX (FIX) concentrates that carry molecular modifications to extend their half‐life, arguing for the need for careful analysis of new HB treatment modalities with respect to FIX assay performance.
← all excerpts
Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy.
1
—
—